**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 53644

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Delirium, insulin-like growth factor i, growth hormone in older inpatients**

Adamis D *et al*. Levels of IGF-I and GH in delirium

Dimitrios Adamis, Iulian Coada, Piet Eikelenboom, Che-Sheng Chu, Karen Finn, Vincent Melvin, John Williams, David James Meagher, Geraldine McCarthy

**Dimitrios Adamis, Iulian Coada, Vincent Melvin, Geraldine McCarthy,** Department of Psychiatry, Sligo/Leitrim Mental Health Services, Sligo F91 CD34, Ireland

**Dimitrios Adamis,** Department of Psychiatry, Research and Academic Institute of Athens, Athens 11742, Greece

**Dimitrios Adamis, David James Meagher,** Department of Psychiatry, University Hospital Limerick, Limerick V94 F858, Ireland

**Piet Eikelenboom,** Department of Psychiatry, GGZinGeest and VuMC, Amsterdam 1081 HV, the Netherlands

**Che-Sheng Chu,** Department of Psychiatry and Center for Geriatric and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan

**Karen Finn,** Department of Biopharmaceutical and Medical Science, School of Science and Computing, Galway-Mayo Institute of Technology, Galway H91 T8NW, Ireland

**John Williams,** Department of Pathology, Sligo University Hospital, Sligo F91 H684, Ireland

**Author contributions:** Adamis D was involved in the conceptualization of the project, data curation, statistical analysis, supervision of the project, writing-original draft; Coada I was involved in data entry, curation, writing-original draft; Eikelenboom P was involved in the conceptualization, supervision of the project, writing-original draft; Chu C was involved in the in the conceptualization, supervision, and writing-original draft; Finn K was involved in the biochemical analysis, data entry, data curation, writing-original draft; Melvin V was involved in the clinical data collection, data entry and curation, writing-original draft; Williams J was involved in the conceptualization, biochemical analysis, supervision, funding acquisition and writing the original draft; Meagher D was involved in the conceptualization, supervision, and writing the original draft; McCarthy G was involved in the conceptualization, supervision, funding acquisition and writing the original draft; all authors have contributed read and approve the final manuscript.

**Supported by** Research Seedgrant fromtheResearch and Education Foundation, Sligo University Hospital, Sligo, Ireland.

**Corresponding author: Dimitrios Adamis, MD, MSc, Academic Research,** Department of Psychiatry, Sligo/Leitrim Mental Health Services, Clarion Road, Sligo F91 CD34, Ireland. dimaadamis@yahoo.com

**Received:** December 30, 2019

**Revised:** June 16, 2020

**Accepted:** August 24, 2020

**Published online:**

**Abstract**

BACKGROUND

Delirium is a common disorder in elderly medical inpatients with serious adverse outcomes and is characterized by sudden onset, disturbance in attention, awareness, consciousness and cognition, and often with behavioural disturbances. Central to understanding delirium, is understanding mechanisms by which body and brain wellbeing are linked and in particular how brain responses to bodily homeostatic stress is mediated. A number of studies have investigated the relationship between insulin-like growth factor I (IGF-I) and delirium in medically ill hospitalised patients with conflicting results. However, none have investigated growth hormone (GH) which is related to IGF-I *via* negative feedback.

AIM

To investigate the relationship between serum levels of IGF-I and GH, and the occurrence of delirium.

METHODS

Prospective, longitudinal, observational study. Consecutive elderly inpatients (aged 70+), were assessed twice weekly with montreal cognitive assessment (MoCA), Confusion assessment method (CAM), Acute Physiology and Chronic Health Evaluation II. Delirium was defined using CAM. Previous history of dementia was evaluated with the Informant Questionnaire on Cognitive Decline in the Elderly. IGF-I and GH levels were estimated with the ELISA method. Generalized estimating equations (GEE) model was applied for the first five assessments to analyze those longitudinal data.

RESULTS

The sample consisted of 198 participants (mean age 80.63 ± 6.81; range 70-97). Of these 92 (46.5%) were females. Eighty six (43.4%) were identified with a history of dementia. Incident or prevalent delirium during hospitalisation was identified with CAM in 40 participants (20.2%). Evaluation of missing values with Little's MCAR test indicated that they were missing completely at random (MCAR *χ2* = 12.24, *u*: 9, *P* = 0.20). Using GEE for the analysis we found that low MoCA scores, low levels of IGF-I and high levels of GH were significantly associated with any delirium (prevalence, incident, or fluctuating , during the study period (Wald *χ*2 = 12.231; *u*: 1, *P* < 0.001, Wald *χ*2 = 7.196, *u*: 1, *P* = 0.007, Wald *χ*2 = 6.210; : *u:* 1, *P* = 0.013 respectively).

CONCLUSION

The results show that low levels of IGF-I, high levels of GH and low scores in cognition are independently associated with the occurrence of any delirium during the hospitalisation of medically ill older people. The results of the study supports the hypothesis that deficits in the immunoreactivity of the brain (low cerebral reserve) may be associated with delirium.

**Key words:** Delirium; Pathophysiology; Insulin-like growth factor-I; Growth hormone; older people; physical illness; Cognition; Old age psychiatry

Adamis D, Coada I, Eikelenboom P, Chu CS, Finn K, Melvin V, Williams J, Meagher DJ, McCarthy G. Delirium, insulin-like growth factor I, growth hormone in older inpatients. *World J Psychiatr* 2020; In press

**Core tip:** The present work investigates the association of serum levels of insulin-like growth factor I (IGF-I) and growth hormone (GH) with delirium presence in older medically ill hospitalised people. We found, in accordance with previous studies, that low levels of serum IGF-I and high levels of GH together with cognitive deficits are associated with the occurrence of delirium.

**INTRODUCTION**

Delirium is a syndrome which often presented with sudden onset, and disorders of the cognitive, consciousness, motor, affective, and perceptual domains. Those disturbances often are fluctuated[1]. It also manifested with different motor subtypes like hyperactive, hypoactive or mixed states[2].

Delirium is a common disorder in elderly medical inpatients. In Irish hospitals the point prevalence of delirium is estimated around 20%[3]. Higher rates are reported among patients in palliative and intensive care settings[3,4]. Delirium has severe bad consequences like, delays in hospital discharges increased hospital budgets[5], higher rates of institutionalisation[6], and perhaps increased mortality[7]. The old-fashioned concept of delirium as a brief, transient, and highly reversible condition is no longer supported by longitudinal studies. Accumulating evidence support that delirium is associated with persistent cognitive and functional problems[8,9] and delirium may be an accelerating and possibly causal factor in the development of dementia[10]. Notably, these adverse outcomes are independent of the severity of physical illness that cause delirium. Despite the understanding that delirium is caused by physical illness, it is not clear yet how those physical causes without direct connection with brain, can produce such a consistent complex neuropsychiatric picture as found in delirium. Thus, the pathophysiology of delirium remains unclear and many pathophysiological mechanisms have been hypothesised and suggested but none yet proved[5,11].

Delirium often occurs in the context of infectious illness and the external administration of cytokines in a number of medical illness for therapeutic reasons, can results to delirium. Thus, in an effort to clarify the pathophysiology of delirium a number of studies have investigated cytokine levels, but the results are conflicted and inconclusive[12]. However, from our previous work[13] we found that low circulating levels of neuroprotective factors of IGF-1 and interleukin-1 receptor antagonist (IL-1RA) were connected with delirium. Although there are few studies with firm conclusions about the role of cytokines in delirium, a hypothesis in which we work is that cerebral deficits may be the reason for the occurrence of delirium. This has led our research group to work on the general hypothesis that delirium is associated with already existed deficits in the brain regarding the immunoreactivity and the readiness to respond to the external “insult” (*e.g.*, physical illness). Low levels of neuroprotective factors may possibly explain the onset of delirium rather than the actual trigger or “insult” factor. This can explain the observations that the severity of physical illness is not a risk factor for delirium at least in older populations[14]. One of those neuroprotective factors which has been investigated in delirium is the IGF-I.

IGF-I is regulate the body growth and metabolism but involves also in different brain functions. Circulating IGF-I is produced mainly from the liver but it can be produced by any cell type. The receptors of IGF-I are on almost all different cells including brain and have neuroprotective effects[15,16]. In addition IGF-I receptors play significant role in the integrity and regulation of blood-brain barrier, they have high expression in the cells that constitute it and they facilitate the access of serum IGF-I to entry into the brain[17].

In the Central Nervous System the IGF-I is produced by neurons and glial cells[18] and plays an extensive role in the development, plasticity and survival of neurons. IGF-I involves in the production of neurotransmitters, blocks apoptosis in damaged neurons, and thus has effects on cognition and cognitive decline during ageing or in other neurocognitive disorders like dementia and delirium[16,19-21].

However, IGF-I is not independent. The secretion of IGF-I is under the control of growth hormone (GH) which is called the GH/IGF-1 axis. GH is pleiotropic hormone which regulates many functions like feeding, growth, metabolism, reproduction, and immune system function. The secretion of GH is stimulated by the GHRH from the hypothalamus. GH secretion is also influenced by IGF-I, which involves a negative feedback mechanism[22,23].

Higher levels of GH are associated with risen levels IGF-I until a certain point where a plateau is reached[24]. It has been reported[25] that cerebrospinal levels of somatostatin (Growth hormone Inhibiting hormone) are significantly lower during delirium but and later at follow-up. This does not indicate a directly link between delirium and GH, but indicates a disturbed GH/IGF-1 axis in delirium. In the same line, in patients admitted to the intensive care unit it was found that low levels of IGF-I were correlated with high levels of GH[26]. In addition, a study[27] reported that administration of human GH in aged women following hip operation had increased IGF-I levels. Therefore, until now we do not know the way of the interaction of GH and IGF-I during delirium. In our previous review we have identified a lack of research work in relation to GH in studies which investigated IGF-I and delirium[12].

Nevertheless, a number of studies have investigated the relationship of IGF-I with delirium in medically ill hospitalised patients as well as in patients undergoing surgery with conflicting results. A resent meta-analysis[28] showed that there are indications of an association of IGF-1 and delirium but the authors also calling for further research into this area.

Given the previous studies and the new updates we carried out a new study in older medically ill hospitalised patients with the aim to find out the relationship of the circulating levels of IGF-I and GH to the delirium (in both prevalent and incident).

**MATERIALS AND METHODS**

The present study was designed as a pragmatic prospective, longitudinal study. The study was carried out in a University Hospital in Sligo in the North-West of Ireland. The inclusion criteria were: (1) consecutive admitted patients in the elderly medical wards; and (2) to be 70 years old and above. Exclusion criteria were (1) patients who were readmitted and had already participate in the study; (2) patients intubated or with aphasia; (3) patients in a terminal stage of illness; and (4) patients unable to speak English. A time frame of 72 h since admission was in place for the assessment of the eligibility for recruitment and the recruitment of participants.

***Procedure***

Those patients who fulfilled the inclusion criteria and consented had an assessment at first day. Then seven more assessments were followed in a regular space of 3 ± 1 d if they were still hospitalised and alive. The maximum number of assessment was eight. Non-fasting blood was withdrawn the same days of the assessments. Bloods were centrifuged within ten minutes and then stored at -70 °C until analysis. Levels of IGF-I and GH were estimated with the ELISA method. Levels of IGF-I are measured in ng/ml and levels of GH in pg/ml.

***Assessments and scales***

Demographic data were collected from the computer of the hospital database. In addition at each time the following measurements/scales were administered.

***Cognitive scale***

The Montreal Cognitive Assessment (MoCA)[29] have been used for assessment of cognition. The maximum score in MoCA is 30 which indicates an intact cognition. In participants who were unable to complete all the sections due to a physical disability (*e.g.*, visual impairment) MoCA results were standardized to give a maximum score of 30. To complete the MoCA it takes about 12-15 min.

***Assessment/scale for delirium***

The presence/absence of delirium was assessed with the CAM scale/algorithm[30]. The CAM is based in DSM-IIIR criteria for delirium. It asses four “cardinal” criteria for delirium.

***Physical illness***

To assess the severity of the underling physical illness the Acute Physiology and Chronic Health Evaluation II (APACHE-II)[31] (Acute Physiology and Chronic Health Evaluation II) and the APS subscale (Acute Physiology Score) were used. Higher scores in both scales indicate more illness severity.

***Diagnosis of previous history of dementia***

Pre-existing dementia was assessed with two ways. First if it was documented clearly according to DSM-IV diagnostic criteria or if not the Short Informant Questionnaire of Cognitive Decline was used by interviewing the nearest relative. The cut-off point of ≥ 3.5[32] was used to define pre-existing dementia.

***Ethical considerations***

Informed consent was in writing using an earlier described method[33]. A separate consent in writing was asked for phlebotomy. The Sligo University Hospital Research Ethics Committee has graded Ethical approval for the project.

***Statistical analysis***

SPSS v23 was used for the analysis of the data. Continuous variables were presented as mean ± SD and categorical as counts and percentages. The Generalized Estimating Equations (GEE) method was used to analyse the effects of independent variables on delirium. GEE adjusts for correlations due to repeated assessments of each participant[34].Because the dependent variable (delirium/no delirium) was binary the binominal distribution was used. To evaluate the fit of the model the Corrected Quasi Likelihood under Independence Model Criterion (QICC) value was used, (lower value – better fit). Because there were many missing values in the last 3 assessments (drop-outs) only the first 5 will be entered to the model.

**RESULTS**

***Description of the sample***

A total of 198 participants were analysed. The mean age of the participants was 80.63 ± 6.81; range 70-97. Of these 106 (53.5%) were males. Previous history of dementia was found in eighty six (43.4%). The characteristics of the two groups (delirium/ no delirium) at each of the five assessments, including means and standard deviations of the scales MoCA, and APACHE II scores, and IGF-I and GH levels at each assessment are shown in table 1. Figure 1 shows the mean levels of IGF-I and GH across the assessments for those with and without delirium.

***Evaluation of missing data***

This was done by using the Little's MCAR test. The results of the test was not significant (MCAR, *χ*2 = 12.24, *u:* 9, *P* = 0.20) which indicates that the missing values were missing completely at random

***Longitudinal analysis: GEE model***

Here we examined the effects of the independent variables age, gender, previous history of dementia (binary yes/no), APACHE II, MoCA scores, and the levels of IGF-I and GH on the dependent variable delirium/no delirium (binary). The most parsimonious model (lowest QICC value) is shown in table 2.

The results from the table 2 shows that those with any delirium during the hospitalisation had significantly lower scores in the MoCA scale, lower levels of IGF-I and higher levels of GH compared to those without delirium. None of the other examined variables (age, gender, previous history of dementia or severity of physical illness (APACHE II) had any significant effect in the presence or absence of delirium as it was defined with CAM.

**DISCUSSION**

First of all, the results show that deficits in cognition as measured with the MoCA, are a significant independent predictor for the occurrence of any delirium (prevalent, incident, or fluctuating). This result is constantly found in all the studies which investigate delirium because disturbance in cognition is a central feature of delirium. Therefore this is a result which was expected. In addition the severity of the physical illness (as measured with APACHE II), previous history of dementia, and age did not have any effect on delirium. Severity of physical illness again is an expected finding since in our previous studies we did not find any effect and thus we generate the hypothesis that it is not the severity of insult that is important for causing the delirium but the reduced neuroprotection of the brain. Besides the lack of effect of age and previous history of dementia is easily explained by the more powerful predictor, scores in the MoCA.

Regarding the IGF-I, the results of the present study is in accordance with our previous study[13] in which we use similar methodology and longitudinal design but in a different population, different hospital and in a different country and also confirmed that low levels of circulating IGF-I are significantly linked with any delirium (incident or prevalence). Similar results have been reported form other research groups[35-39], but not from all[40-43]. However a resent meta-analysis[28] showed that lower levels of circulating IGF-I are associated with higher rates of delirium among older patients. There are many reasons for those discrepancies among the studies, (see also[28]). First of all different populations were studied. Some studies include populations with pre-existing dementia (*e.g.*, the present study) while others excluded them[41,42]. A second reason perhaps is the setting where the study is conducted and the sample. Some of the studies were conducted in medical wards where the sample include populations with mainly medical illness while others in surgical wards in patients before and after surgery. Perhaps surgery is another stressor and perhaps pathophysiology which leads to delirium in those patients is different despite the end product being the same. In addition those studies in surgery wards have examined patients before and immediately after the surgery for delirium. However, it has been suggested that perhaps different mechanisms are underline the delirium that developed in the first 24 hours after surgery and in the delirium that developed the next one to three days after surgery[44]. Finally one important reason which can explain those discrepancies is the different scales/measurements/criteria that have been applied to define delirium. It has been shown that applying different criteria for delirium is influence significantly the rates and diagnosis of delirium and there is extensive discrepancy between the actual cases defined by each different system[45-48].

Furthermore, the present study for first time shows that GH is an important factor in the pathogenesis of delirium. However, because IGF-I and GH are correlated with a negative loop feedback we do not know which of them is more important in the pathogenesis of delirium. From the present study what we can conclude is that the somatotropic axis (IGF-I/GH) is disturbed during the delirium phase compared to those without delirium. Low IGF-I and high GH levels are related to delirium. To the best of our knowledge no previous studies have investigated the IGF-I/GH axis. Therefore we attempt to explain our hypothesis further.

The secretion of GH is age related and a decline of GH started between the ages of 18 to 25 years. This decrease of the GH concentration in the periphery is accompanied by a gradual decline of IGF-I as well[27,49]. In addition, lower levels of GH are correlated with frailty[27] and exogenous administration of GH can increase energy, and improve mood, concentration, and memory. Those improvements in cognition may are the results of a direct effect of GH in the brain[50,51]. Therefore, perhaps the increased levels of GH reflect a compensatory mechanism in the brain to recover through a direct effect of GH. However, this does not explain the low levels of IGF-I which interestingly have been proven to protect neurons directly[52]. Experimental studies in animals have shown that after administration of IGF-I in brain injuries there was an improvement in the outcomes (regarding behaviour and cognition)[53]. IGF-I has also been proposed as a treatment for Alzheimer’s disease because it play a crucial role in tau pathway and acetyl-choline which both connected with the occurrence of delirium[54]. Therefore a direct effect of IGF-I is more likely than a direct effect of GH. In the same line a second explanation has been suggested that in acute inflammation situations there is a GH resistance because the body prevents growth and energy storage in an attempt to keep the homeostasis. In those situations of acute inflammation the levels of IGF-I reduced, regardless of the increase of GH[41,55].

Taken together those suggestions provide a likely explanation that in delirious states GH is increased because of the disturbed IGF-I / GH axis and the lack of inhibitory mechanism of IGF-I.

Whatever mechanism is involved we cannot conclude from this study and it is important to notice that we measure levels in the periphery which may or may not reflect the brain levels of IGF-I and GH. However, we can conclude that in delirium the IGF-I/GH axis is disturbed, and that low levels of IGF-I together with high levels of GH and impaired cognition are independently significant predictors of delirium.

Limitations of the study

An obvious and common limitation of those kinds of studies including the present is the small sample size. However, the drop-outs and missing data of the study were completely missing at random so no biases have introduced in the study. A second limitation of the study is the lack of generalizability. The results of this study apply only in medically ill older people and not in other populations. Perhaps similar studies are needed also in other populations like surgical patients. There are ongoing collaborative studies examined the role of serum factors in postoperative delirium. Surgery induced delirium is a good model to separate the predisposal factors (preoperative) from the precipitating factors (post-operative) in the occurrence of delirium. Furthermore, the strengths of his study are the longitudinal design and the statistical analysis accompanied the design. By having this design and analysis we have included all the deliria during hospitalisation (prevalence, incident, fluctuated, and persistent) compared with the non-delirium states (including never delirium during hospitalisation and recovered delirium) across the time in the entire examined population.

***Implications of the study***

As we noted above, further studies need to be done in different populations before we be asserted about the results. If the results are replicated in further studies this can lead to clinical trials for the treatment and / or prevention of delirium with small doses of IGF-I.

**CONCLUSION**

In conclusion, this study indicates that during delirium in older medically ill hospitalised patients the IGF-I/GH axis is disturbed but we do not know yet the mechanism behind it. However more studies are needed to confirm or disconfirm the above findings before we move further to clinical trials for treatment or prevention of delirium with small doses of IGF-I.

**ARTICLE HIGHLIGHTS**

***Research background***

Delirium is a common disorder in elderly medical inpatients, in surgical wards, and Intensive care units with serious adverse outcomes.

***Research motivation***

To understand delirium is important to understand the underline mechanisms by which body and brain are linked and how brain responses to bodily homeostatic stress is mediated. We have notice from our previous research work that the severity of physical illness is not a risk factor for delirium at least in older populations and perhaps delirium is associated with deficits in the immunoreactivity of the brain (low cerebral reserve). Low levels of neuroprotective factors may possibly explain the onset of delirium rather than the actual trigger or “insult” factor. A number of studies have investigated the relationship between Insulin-like growth factor I (IGF-I) and delirium with conflicting results. A relevant also factor is the Growth Hormone (GH) which is related to IGF-I *via* negative feedback. Therefore in the present study we included also the GH.

***Research objectives***

To investigate the relationship of the occurrence of delirium during hospitalisation (prevalent and incident) with the serum levels of IGF-I and GH.

***Research methods***

Observational, prospective, longitudinal study of older people who consecutively admitted to medical wards of a general hospital.

***Research results***

We found that low cognitive function, low levels of IGF-I and high levels of GH were significantly associated with any delirium (prevalence, incident, or fluctuating) during the study period.

***Research conclusions***

The involvement of GH in delirium is a new finding from the present study. Also the finding of the low levels of IGF-I and the association of delirium confirms some of the previous studies. Those findings together with the association of cognitive decline with delirium strength the primary hypotheses that low brain reserves are possible the predisposing factor for delirium. Those findings needs further replication in other studies and especially in surgical samples

***Research perspectives***

If the above findings are replicated in future studies then the next step is clinical trials with small doses of IGF-I for prevention of delirium.

**REFERENCES**

1 **American Psychiatric Association.** Task Force on DSM-IV. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994: 886

2 **Meagher DJ**, Leonard M, Donnelly S, Conroy M, Adamis D, Trzepacz PT. A longitudinal study of motor subtypes in delirium: frequency and stability during episodes. *J Psychosom Res* 2012; **72**: 236-241 [PMID: 22325705 DOI: 10.1016/j.jpsychores.2011.11.013]

3 **Ryan DJ**, O'Regan NA, Caoimh RÓ, Clare J, O'Connor M, Leonard M, McFarland J, Tighe S, O'Sullivan K, Trzepacz PT, Meagher D, Timmons S. Delirium in an adult acute hospital population: predictors, prevalence and detection. *BMJ Open* 2013; **3**: [PMID: 23299110 DOI: 10.1136/bmjopen-2012-001772]

4 **Adamis D,** Macdonald AJ. Prevalence, Incidence (Epidemiology) and Associations (Risk Factors) of Delirium in Elderly Medical Inpatients. In: Newman KJ, Slater TC, editors. Delirium: Causes, Diagnosis and Treatment. Neuroscience Research Progress Psychiatry - Theory, Applications and Treatments. Hauppauge NY: Nova Science Publishers; 2012: 49-75

5 **Inouye SK**, Westendorp RG, Saczynski JS. Delirium in elderly people. *Lancet* 2014; **383**: 911-922 [PMID: 23992774 DOI: 10.1016/s0140-6736(13)60688-1]

6 **Adamis D**, Treloar A, Martin FC, Macdonald AJ. Recovery and outcome of delirium in elderly medical inpatients. *Arch Gerontol Geriatr* 2006; **43**: 289-298 [PMID: 16434113 DOI: 10.1016/j.archger.2005.11.005]

7 **Witlox J**, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. *JAMA* 2010; **304**: 443-451 [PMID: 20664045 DOI: 10.1001/jama.2010.1013]

8 **Adamis D**, Meagher D, Treloar A, Dunne C, Larvin M, Martin FC, Macdonald AJ. Phenomenological and biological correlates of improved cognitive function in hospitalized elderly medical inpatients. *Arch Gerontol Geriatr* 2014; **59**: 593-598 [PMID: 25189345 DOI: 10.1016/j.archger.2014.08.007]

9 **MacLullich AM**, Beaglehole A, Hall RJ, Meagher DJ. Delirium and long-term cognitive impairment. *Int Rev Psychiatry* 2009; **21**: 30-42 [PMID: 19219711 DOI: 10.1080/09540260802675031]

10 **Davis DH**, Muniz Terrera G, Keage H, Rahkonen T, Oinas M, Matthews FE, Cunningham C, Polvikoski T, Sulkava R, MacLullich AM, Brayne C. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. *Brain* 2012; **135**: 2809-2816 [PMID: 22879644 DOI: 10.1093/brain/aws190]

11 **Maldonado JR**. Acute Brain Failure: Pathophysiology, Diagnosis, Management, and Sequelae of Delirium. *Crit Care Clin* 2017; **33**: 461-519 [PMID: 28601132 DOI: 10.1016/j.ccc.2017.03.013]

12 **Adamis D**, Meagher D. Insulin-like growth factor I and the pathogenesis of delirium: a review of current evidence. *J Aging Res* 2011; **2011**: 951403 [PMID: 21766035 DOI: 10.4061/2011/951403]

13 **Adamis D**, Lunn M, Martin FC, Treloar A, Gregson N, Hamilton G, Macdonald AJ. Cytokines and IGF-I in delirious and non-delirious acutely ill older medical inpatients. *Age Ageing* 2009; **38**: 326-32; discussion 251 [PMID: 19269948 DOI: 10.1093/ageing/afp014]

14 **Adamis D.** Cytokines in the elderly. In: Preedy VR, Hunter R, editors. Cytokines: Taylor & Francis; 2011: 79-92 [DOI: 10.1201/b11037-9]

15 **Kim B**, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. *Exp Mol Med* 2015; **47**: e149 [PMID: 25766618 DOI: 10.1038/emm.2015.3]

16 **Kim B**, Elzinga SE, Henn RE, McGinley LM, Feldman EL. The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease. *Neurobiol Dis* 2019; **132**: 104541 [PMID: 31349033 DOI: 10.1016/j.nbd.2019.104541]

17 **Labandeira-Garcia JL**, Costa-Besada MA, Labandeira CM, Villar-Cheda B, Rodríguez-Perez AI. Insulin-Like Growth Factor-1 and Neuroinflammation. *Front Aging Neurosci* 2017; **9**: 365 [PMID: 29163145 DOI: 10.3389/fnagi.2017.00365]

18 **Rodriguez-Perez AI**, Borrajo A, Diaz-Ruiz C, Garrido-Gil P, Labandeira-Garcia JL. Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging. *Oncotarget* 2016; **7**: 30049-30067 [PMID: 27167199 DOI: 10.18632/oncotarget.9174]

19 **Nieto-Estévez V**, Defterali Ç, Vicario-Abejón C. IGF-I: A Key Growth Factor that Regulates Neurogenesis and Synaptogenesis from Embryonic to Adult Stages of the Brain. *Front Neurosci* 2016; **10**: 52 [PMID: 26941597 DOI: 10.3389/fnins.2016.00052]

20 **Wrigley S**, Arafa D, Tropea D. Insulin-Like Growth Factor 1: At the Crossroads of Brain Development and Aging. *Front Cell Neurosci* 2017; **11**: 14 [PMID: 28203146 DOI: 10.3389/fncel.2017.00014]

21 **Tien LT**, Lee YJ, Pang Y, Lu S, Lee JW, Tseng CH, Bhatt AJ, Savich RD, Fan LW. Neuroprotective Effects of Intranasal IGF-1 against Neonatal Lipopolysaccharide-Induced Neurobehavioral Deficits and Neuronal Inflammation in the Substantia Nigra and Locus Coeruleus of Juvenile Rats. *Dev Neurosci* 2017; **39**: 443-459 [PMID: 28787734 DOI: 10.1159/000477898]

22 **Qiu H**, Yang JK, Chen C. Influence of insulin on growth hormone secretion, level and growth hormone signalling. *Sheng Li Xue Bao* 2017; **69**: 541-556 [PMID: 29063103 DOI: 10.13294/j.aps.2017.0062]

23 **Bergan-Roller HE**, Sheridan MA. The growth hormone signaling system: Insights into coordinating the anabolic and catabolic actions of growth hormone. *Gen Comp Endocrinol* 2018; **258**: 119-133 [PMID: 28760716 DOI: 10.1016/j.ygcen.2017.07.028]

24 **Barkan AL**. Defining normalcy of the somatotropic axis: an attainable goal? *Pituitary* 2007; **10**: 135-139 [PMID: 17410470 DOI: 10.1007/s11102-007-0029-7]

25 **Koponen HJ**, Leinonen E, Lepola U, Riekkinen PJ. A long-term follow-up study of cerebrospinal fluid somatostatin in delirium. *Acta Psychiatr Scand* 1994; **89**: 329-334 [PMID: 7915078 DOI: 10.1111/j.1600-0447.1994.tb01524.x]

26 **Ross R**, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. *Clin Endocrinol (Oxf)* 1991; **35**: 47-54 [PMID: 1909610 DOI: 10.1111/j.1365-2265.1991.tb03495.x]

27 **Yeo AL**, Levy D, Martin FC, Sönksen P, Sturgess I, Wheeler MM, Young A. Frailty and the biochemical effects of recombinant human growth hormone in women after surgery for hip fracture. *Growth Horm IGF Res* 2003; **13**: 361-370 [PMID: 14624771 DOI: 10.1016/j.ghir.2003.08.001]

28 **Li DJ**, Tseng PT, Stubbs B, Chen TY, Lin PY, Chen SL, Thompson T, Adamis D, Chu CS. Low peripheral levels of insulin growth factor-1 are associated with high incidence of delirium among elderly patients: A systematic review and meta-analysis. *Arch Gerontol Geriatr* 2018; **77**: 13-18 [PMID: 29605680 DOI: 10.1016/j.archger.2018.03.011]

29 **Nasreddine ZS**, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; **53**: 695-699 [PMID: 15817019 DOI: 10.1111/j.1532-5415.2005.53221.x]

30 **Inouye SK**, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med* 1990; **113**: 941-948 [PMID: 2240918 DOI: 10.7326/0003-4819-113-12-941]

31 **Knaus WA**, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med* 1985; **13**: 818-829 [PMID: 3928249 DOI: 10.1097/00003246-198510000-00009]

32 **Jorm AF**. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. *Psychol Med* 1994; **24**: 145-153 [PMID: 8208879 DOI: 10.1017/s003329170002691x]

33 **Adamis D**, Martin FC, Treloar A, Macdonald AJ. Capacity, consent, and selection bias in a study of delirium. *J Med Ethics* 2005; **31**: 137-143 [PMID: 15738432 DOI: 10.1136/jme.2002.000919]

34 **Adamis D**. Statistical methods for analysing longitudinal data in delirium studies. *Int Rev Psychiatry* 2009; **21**: 74-85 [PMID: 19219714 DOI: 10.1080/09540260802675346]

35 **Wilson K**, Broadhurst C, Diver M, Jackson M, Mottram P. Plasma insulin growth factor-1 and incident delirium in older people. *Int J Geriatr Psychiatry* 2005; **20**: 154-159 [PMID: 15660412 DOI: 10.1002/gps.1265]

36 **Morandi A**, Gunther ML, Pandharipande PP, Jackson JC, Thompson JL, Shintani AK, Ely EW, Girard TD. Insulin-like growth factor-1 and delirium in critically ill mechanically ventilated patients: a preliminary investigation. *Int Psychogeriatr* 2011; **23**: 1175-1181 [PMID: 21294938 DOI: 10.1017/s1041610210002486]

37 **Çinar MA**, Balikçi A, SertoÄŸlu E, Mehmet AK, Serdar MA, Özmenler KN. Role of CRP, TNF-a, and IGF-1 in Delirium Pathophysiology. *Noro Psikiyatr Ars* 2014; **51**: 376-382 [PMID: 28360657 DOI: 10.5152/npa.2014.6999]

38 **Egberts A**, Wijnbeld EH, Fekkes D, van der Ploeg MA, Ziere G, Hooijkaas H, van der Cammen TJ, Mattace-Raso FU. Neopterin: a potential biomarker for delirium in elderly patients. *Dement Geriatr Cogn Disord* 2015; **39**: 116-124 [PMID: 25413160 DOI: 10.1159/000366410]

39 **Shen H**, Shao Y, Chen J, Guo J. Insulin-Like Growth Factor-1, a Potential Predicative Biomarker for Postoperative Delirium Among Elderly Patients with Open Abdominal Surgery. *Curr Pharm Des* 2016; **22**: 5879-5883 [PMID: 27526790 DOI: 10.2174/1381612822666160813234311]

40 **Lemstra AW**, Kalisvaart KJ, Vreeswijk R, van Gool WA, Eikelenboom P. Pre-operative inflammatory markers and the risk of postoperative delirium in elderly patients. *Int J Geriatr Psychiatry* 2008; **23**: 943-948 [PMID: 18481319 DOI: 10.1002/gps.2015]

41 **Cerejeira J**, Batista P, Nogueira V, Vaz-Serra A, Mukaetova-Ladinska EB. The stress response to surgery and postoperative delirium: evidence of hypothalamic-pituitary-adrenal axis hyperresponsiveness and decreased suppression of the GH/IGF-1 Axis. *J Geriatr Psychiatry Neurol* 2013; **26**: 185-194 [PMID: 23864592 DOI: 10.1177/0891988713495449]

42 **Yen TE**, Allen JC, Rivelli SK, Patterson SC, Metcalf MR, Flink BJ, Mirrakhimov AE, Lagoo SA, Vail TP, Young CC, Moon RE, Trzepacz PT, Kwatra MM. Association between Serum IGF-I levels and Postoperative Delirium in Elderly Subjects Undergoing Elective Knee Arthroplasty. *Sci Rep* 2016; **6**: 20736 [PMID: 26846868 DOI: 10.1038/srep20736]

43 **Chu CS**, Liang CK, Chou MY, Lin YT, Hsu CJ, Chu CL, Chou PH. Lack of Association between Pre-Operative Insulin-Like Growth Factor-1 and the Risk of Post-Operative Delirium in Elderly Chinese Patients. *Psychiatry Investig* 2016; **13**: 327-332 [PMID: 27247600 DOI: 10.4306/pi.2016.13.3.327]

44 **Slor CJ**, Witlox J, Adamis D, Jansen RWMM, Houdijk APJ, van Gool WA, de Jonghe JFM, Eikelenboom P. The trajectory of C-reactive protein serum levels in older hip fracture patients with postoperative delirium. *Int J Geriatr Psychiatry* 2019; **34**: 1438-1446 [PMID: 31058343 DOI: 10.1002/gps.5139]

45 **Laurila JV**, Pitkala KH, Strandberg TE, Tilvis RS. Impact of different diagnostic criteria on prognosis of delirium: a prospective study. *Dement Geriatr Cogn Disord* 2004; **18**: 240-244 [PMID: 15286453 DOI: 10.1159/000080022]

46 **Thomas C**, Kreisel SH, Oster P, Driessen M, Arolt V, Inouye SK. Diagnosing delirium in older hospitalized adults with dementia: adapting the confusion assessment method to international classification of diseases, tenth revision, diagnostic criteria. *J Am Geriatr Soc* 2012; **60**: 1471-1477 [PMID: 22881707 DOI: 10.1111/j.1532-5415.2012.04066.x]

47 **Meagher DJ**, Morandi A, Inouye SK, Ely W, Adamis D, Maclullich AJ, Rudolph JL, Neufeld K, Leonard M, Bellelli G, Davis D, Teodorczuk A, Kreisel S, Thomas C, Hasemann W, Timmons S, O'Regan N, Grover S, Jabbar F, Cullen W, Dunne C, Kamholz B, Van Munster BC, De Rooij SE, De Jonghe J, Trzepacz PT. Concordance between DSM-IV and DSM-5 criteria for delirium diagnosis in a pooled database of 768 prospectively evaluated patients using the delirium rating scale-revised-98. *BMC Med* 2014; **12**: 164 [PMID: 25266390 DOI: 10.1186/s12916-014-0164-8]

48 **Adamis D**, Rooney S, Meagher D, Mulligan O, McCarthy G. A comparison of delirium diagnosis in elderly medical inpatients using the CAM, DRS-R98, DSM-IV and DSM-5 criteria. *Int Psychogeriatr* 2015; **27**: 883-889 [PMID: 25601222 DOI: 10.1017/s1041610214002853]

49 **Giustina A**, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. *Endocr Rev* 1998; **19**: 717-797 [PMID: 9861545 DOI: 10.1210/er.19.6.717]

50 **Khorram O**. Use of growth hormone and growth hormone secretagogues in aging: help or harm. *Clin Obstet Gynecol* 2001; **44**: 893-901 [PMID: 11600869 DOI: 10.1097/00003081-200112000-00026]

51 **Arwert LI**, Veltman DJ, Deijen JB, van Dam PS, Drent ML. Effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients: a functional MRI study. *Neuroendocrinology* 2006; **83**: 12-19 [PMID: 16707911 DOI: 10.1159/000093337]

52 **Gluckman PD**, Guan J, Williams C, Scheepens A, Zhang R, Bennet L, Gunn A. Asphyxial brain injury--the role of the IGF system. *Mol Cell Endocrinol* 1998; **140**: 95-99 [PMID: 9722175 DOI: 10.1016/s0303-7207(98)00035-5]

53 **Saatman KE**, Contreras PC, Smith DH, Raghupathi R, McDermott KL, Fernandez SC, Sanderson KL, Voddi M, McIntosh TK. Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury. *Exp Neurol* 1997; **147**: 418-427 [PMID: 9344566 DOI: 10.1006/exnr.1997.6629]

54 **Lackey BR**, Gray SL, Henricks DM. Actions and interactions of the IGF system in Alzheimer's disease: review and hypotheses. *Growth Horm IGF Res* 2000; **10**: 1-13 [PMID: 10753587 DOI: 10.1054/ghir.1999.0129]

55 **Mesotten D**, Van den Berghe G. Changes within the growth hormone/insulin-like growth factor I/IGF binding protein axis during critical illness. *Endocrinol Metab Clin North Am* 2006; **35**: 793-805, ix-ix [PMID: 17127147 DOI: 10.1016/j.ecl.2006.09.010]

**Footnotes**

**Institutional review board statement:** The study has been approved from the Sligo University Hospital ethical committee.

**Informed consent statement:** The informed consents were waived.

**Conflict-of-interest statement:** All authors have no any conflicts of interest.

**Data sharing statement:** no sharing of data.

**STROBE statement:** The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Irish Medical Council, No. 406822; and Royal Statistical Society, No. 020637.

**Peer-review started:** December 27, 2019

**First decision:** April 2, 2020

**Article in press:**

**Specialty type:** Psychiatry

**Country/Territory of origin:** Ireland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Hosak L, Shiina A **S-Editor:** Ma YJ **L-Editor: P-Editor:**

**Figure Legends**



**A B**

**Figure 1** **Means of insulin-like growth factor I (A) and growth hormone (B) across the assessments of delirium and no delirium.** IGF-I: insulin-like growth factor I; GH: growth hormone; CAM: Confusion assessment method.

**Table 1 Cases of delirium and no delirium (according to confusion assessment method) with the scores (mean ± SD) of the montreal cognitive assessment, acute physiology and chronic health evaluation II and growth hormone, insulin-like growth factor I levels at each assessment point**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Assessment** | **CAM (*n*)** |  | **MoCA** | **APACHE II** | **IGF-I (ng/ml)** | **GH (pg/ml** |
| **1** | no delirium (173) | mean ± SD | 11.38 ± 7.90 | 8.59 ± 3.68 | 61.32 ± 22.95 | 503.95 ± 743.05 |
| Valid, *n* | 168 | 173 | 68 | 68 |
| delirium (24) | mean ± SD | 3.78 ± 2.76 | 9.00 ± 3.86 | 45.88 ± 14.66 | 693.89 ± 462.15 |
| Valid, *n* | 23 | 24 | 8 | 8 |
| **2** | no delirium (141) | mean ± SD | 10.42 ± 8.23 | 8.69 ± 3.69 | 53.93 ± 18.57 | 434.22 ± 561.88 |
| Valid, *n* | 134 | 140 | 49 | 49 |
| delirium (11) | mean ± SD | 3.67 ± 3.43 | 11.00 ± 5.20 | 41.78 ± 13.98 | 652.14 ± 346.98 |
| Valid, *n* | 9 | 11 | 5 | 5 |
| **3** | no delirium (90) | mean ± SD | 9.27 ± 7.58 | 8.77 ± 3.67 | 60.66 ± 18.88 | 487.98 ± 648.70 |
| Valid, *n* | 84 | 88 | 30 | 30 |
| delirium (13) | mean ± SD | 3.90 ± 2.51 | 10.38 ± 3.69 | 58.29 ± 14.60 | 487.25 ± 507.84 |
| Valid, *n* | 10 | 13 | 5 | 5 |
| **4** | no delirium (58) | mean ± SD | 10.63 ± 7.44 | 8.79 ± 3.55 | 61.97 ± 22.70 | 622.00 ± 790.09 |
| Valid, *n* | 56 | 58 | 18 | 18 |
| delirium (8) | mean ± SD | 6.00 ± 1.83 | 9.00 ± 2.67 | 41.43 ± 8.13 | 577.94 ± 200.90 |
| Valid, *n* | 7 | 8 | 2 | 2 |
| **5** | no delirium (46) | mean ± SD | 8.70 ± 7.20 | 8.80 ± 3.28 | 53.70 ± 14.37 | 288.27 ± 245.51 |
| Valid, *n* | 43 | 46 | 11 | 11 |
| delirium (6) | mean ± SD | 2.33 ± 1.03 | 9.50 ± 3.33 | 42.62 ± 2.42 | 924.34 ± 677.88 |
| Valid, *n* | 6 | 6 | 4 | 4 |

CAM: Confusion assessment method; MoCA: montreal cognitive assessment; APACHE II: acute physiology and chronic health evaluation II; IGF-I: insulin-like growth factor I; GH: growth hormone.

**Table 2 Generalized estimating equations model and parameter estimates of the significant variables on delirium status**

|  |
| --- |
| **Parameter estimates** |
| **Parameter** | **B** | **SE** | **95%CI** | **Hypothesis test** |
| **Lower** | **Upper** | **Wald** ****2** | ***u*** | **Sig.** |
| GH (pg/ml) | -0.0011 | 0.0002 | -0.001 | 0.000 | 6.210 | 1 | 0.013 |
| IGF-1 (ng/ml) | 0.020 | 0.0074 | 0.005 | 0.034 | 7.196 | 1 | 0.007 |
| MoCA | 0.205 | 0.0586 | 0.090 | 0.320 | 12.231 | 1 | < 0.001 |

1The sign (-) shows the direction of the relationship. Reference status: No delirium. GH: Growth hormone; IGF-I: Insulin-like growth factor I; MoCA: Montreal cognitive assessment.